Product
CM-101
Aliases
10 mg/kg CM-101, Anti-human CCL24 monoclonal antibody (CM-101)
5 clinical trials
6 indications
Indication
Primary Sclerosing CholangitisIndication
systemic sclerosisIndication
Non-alcoholic SteatohepatitisIndication
Nonalcoholic SteatohepatitisIndication
Systemic SclerosisIndication
Nonalcoholic Fatty Liver DiseaseClinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects With Primary Sclerosing Cholangitis (The SPRING Study)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Proof of Biology Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic SclerosisStatus: , Estimated PCD: 2026-06-01
Clinical trial
Phase 2A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of CM-101 in Patients With Non-Alcoholic Steatohepatitis (NASH)Status: Completed, Estimated PCD: 2022-08-15
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Phase I Study To Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Subcutaneous Doses of CM-101 in Healthy Male SubjectsStatus: Completed, Estimated PCD: 2019-05-05
Clinical trial
A Phase 1B, Repeated Dose Study, to Evaluate the Safety, PD and PK Profile of CM-101 in NAFLD Patients With Normal Liver Function Tests and Stable NAFLD/NASH Patients With NAFLD Activity Score (NAS) < 3-The SPARK StudyStatus: Completed, Estimated PCD: 2020-04-27